The Food and Drug Administration recently approved a new indication for Eli Lilly's diabetes drug Jardiance.
Jardiance first gained FDA approval in 2014 as a treatment to help lower blood sugar in adults with type 2 diabetes. Now, the drug can also be used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and cardiovascular disease.
The agency's decision is based on results from a postmarket study showing Jardiance reduced deaths by 32 percent in patients with type 2 diabetes who are at risk of heart attack and stroke, according to a Reuters report. Patients in the study also had a 35 percent lower rate of hospitalization for heart failure.
Eli Lilly, who developed the drug through a partnership with German drugmaker Boehringer Ingelheim, can now include data from the postmarket study on the drug's label.
More articles on supply chain:
Supply chain tip of the week: Make hospital supplies visible to help improve workflows
Apple to launch first distribution center in India: 3 things to know
Study: Cancer drugs may stay approved despite proof of inefficacy